Special Risk Warning
- This investment is based on the strategic development needs of Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. (hereinafter referred to as "Kanglong Chemical" or "the Company") and its judgment on the industry market outlook. However, there are uncertainties in industry trends, market conditions, and the business expansion capabilities of the management team, which may impact future operational performance.
- The project is still in the preparatory stage, involving the establishment of a project company, feasibility studies, land use, project approval, environmental protection, planning, and construction matters, which require approval from relevant authorities. Therefore, there are risks of delays, changes, suspension, or termination of the project.
- The project involves a significant investment scale, and the funding sources, usage arrangements, and construction progress may be affected by macroeconomic factors, funding procurement during construction, and changes in credit policies. Investors are advised to be aware of investment risks.
I. Investment Overview
To further enhance the capacity for new drug commercialization production and CDMO R&D services, continuously strengthen the integrated service capabilities for new molecular type projects, solidify core business foundations, and comprehensively improve comprehensive competitiveness and market position, the Company plans to invest approximately RMB 2 billion in Qiantang District, Hangzhou, to establish a new drug commercialization production and CDMO R&D service base. The investment agreement was signed with the Qiantang District Investment Service Center on May 27, 2026. The Company and all members of the board guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or significant omissions.
The matter was approved at the 21st meeting of the third board of directors on May 26, 2026. The signed investment agreement does not constitute a related party transaction and does not constitute a major asset reorganization as defined by the "Administrative Measures for Major Asset Reorganizations of Listed Companies." According to relevant laws and regulations and the Company's articles of association, this matter is within the board's review authority and does not require shareholder meeting approval.